The NemetzGroup
Life-sciences consulting firm founded in 2003 providing strategic and operational support to biopharma organizations across commercialization, medical affairs, and organizational capability building. Core services include go-to-market and launch planning, new product planning and portfolio prioritization, medical affairs design and execution, real-world evidence and HEOR support, executive advisory, and embedded commercialization implementation. The firm also publishes newsletters, hosts events, and maintains case studies documenting client engagements.
Industries
Nr. of Employees
small (1-50)
Products
Digital commercialization planning platform
A software platform to help early- and mid-stage biopharma companies build validated commercialization maps including required headcount and budget plans.
Digital commercialization planning platform
A software platform to help early- and mid-stage biopharma companies build validated commercialization maps including required headcount and budget plans.
Services
C-suite advisory, board presentation support, messaging strategy, and long-range strategic planning.
Commercial assessments, competitive intelligence, multi-year revenue forecasting, TPP development, and portfolio prioritization to support partnering and investment decisions.
Advisory board facilitation, early-access program design support, KOL engagement, publications/congress planning, patient identification/recruitment, and real-world evidence study support.
Interim commercialization leadership, acting go-to-market teams, implementation of functional plans, and vendor selection support.
Organizational design, governance and planning, process development and optimization, training and onboarding, and vendor/external support assessment.
Secondary research synthesis with supplemental primary interviews to inform forecasts, opportunity assessment, and investment or partnering decisions.
C-suite advisory, board presentation support, messaging strategy, and long-range strategic planning.
Commercial assessments, competitive intelligence, multi-year revenue forecasting, TPP development, and portfolio prioritization to support partnering and investment decisions.
Advisory board facilitation, early-access program design support, KOL engagement, publications/congress planning, patient identification/recruitment, and real-world evidence study support.
Interim commercialization leadership, acting go-to-market teams, implementation of functional plans, and vendor selection support.
Organizational design, governance and planning, process development and optimization, training and onboarding, and vendor/external support assessment.
Secondary research synthesis with supplemental primary interviews to inform forecasts, opportunity assessment, and investment or partnering decisions.
Expertise Areas
- Commercial strategy and launch planning
- New product planning and portfolio strategy
- Medical affairs design and execution
- Real-world evidence generation and HEOR
Key Technologies
- Real-world evidence (RWE) study design and analysis
- Health economics and outcomes research (HEOR) methods
- Revenue and market-forecast modeling
- Target product profile (TPP) development
News & Updates
Participation and panel moderation on early and strategic application of real-world evidence.
Attendance and company representation at JPM Healthcare Conference.
Newsletter article offering a checklist and practical guidance for year-end planning, budgeting, resourcing, and aligning priorities for biopharma organizations.
Newsletter with practical leadership guidance for new biopharma leaders.
Article describing how preparation for the JPM conference serves as a forcing function to align corporate and asset-level story, data, and investor-facing materials.
Announcement of internal promotion of Marnie Hoolahan to President.
Participation and panel moderation on early and strategic application of real-world evidence.
Attendance and company representation at JPM Healthcare Conference.
Newsletter article offering a checklist and practical guidance for year-end planning, budgeting, resourcing, and aligning priorities for biopharma organizations.
Newsletter with practical leadership guidance for new biopharma leaders.
Article describing how preparation for the JPM conference serves as a forcing function to align corporate and asset-level story, data, and investor-facing materials.
Announcement of internal promotion of Marnie Hoolahan to President.